Antagonist

Cerevance Expands Series B Financing with Additional $51 Million 

Retrieved on: 
Monday, February 13, 2023
MSD, GV (company), Somnolence, ALS, Protein, Therapy, Safety, Patient, OFF, Schizophrenia, GPR6, CNS, Foresite Capital, DSM-IV codes, Antagonist, Takeda, L-DOPA, KCNK13, Central nervous system, Pharmaceutical industry, Vaccine, Cerev Del, GV, Merck

BOSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced an expansion of its Series B funding round with an additional close of $51 million, bringing the total Series B financing to $116 million. The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.

Key Points: 
  • BOSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced an expansion of its Series B funding round with an additional close of $51 million, bringing the total Series B financing to $116 million.
  • The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.
  • “We are thrilled to secure additional funding from world-class investors who strongly support the need for novel therapies to treat neurological diseases,” said Craig Thompson, chief executive officer of Cerevance.
  • The additional financing announced today includes participation from Gates Frontier, Dementia Discovery Fund, Foresite Capital, GV (Google Ventures), Lightstone Ventures, Takeda Ventures, UPMC Enterprises and Dolby Family Ventures.

Haymarket Medical Education’s Insomnia Working Group Publishes Updated Recommendations for Managing Insomnia Disorder in Primary Care in Primary Care Companion for CNS Disorders (Psychiatrist.com)

Retrieved on: 
Monday, January 23, 2023
Research, Managed Care, Media, Professional Services, Thought Leadership, Mental Health, Continuing, Education, Publishing, Science, Communications, Health, Consensus, Russell, Cognitive behavioral therapy, Journal, Sleep, Wake Forest School of Medicine, FAAFP, Ursinus College, Diagnosis, MI, Safety, Intussusception (medical disorder), Patient, Chronic pain, Depression, University, Behavioral medicine, Antagonist, Henry Ford Hospital, Myenteric plexus, University of Michigan, Quality of life, Insomnia, Doctor of Philosophy, MD, Nursing, Eisai, Medicine, Psychiatry

“A 2023 Update on Managing Insomnia in Primary Care: Insights From an Expert Consensus Group” is the outcome of the March 2022 meeting of The Insomnia Working Group, a consensus panel of insomnia experts in primary care, psychiatry, and clinical research, that included a patient with insomnia.

Key Points: 
  • “A 2023 Update on Managing Insomnia in Primary Care: Insights From an Expert Consensus Group” is the outcome of the March 2022 meeting of The Insomnia Working Group, a consensus panel of insomnia experts in primary care, psychiatry, and clinical research, that included a patient with insomnia.
  • The panel convened to identify gaps in the recognition, diagnosis, and management of insomnia in primary care and to review new data on available and emerging insomnia treatments.
  • The January 24th article details evidence that treating insomnia disorder can result in improvements in comorbid illness and quality of life.
  • Panel members recommend that primary care clinicians proactively screen for evidence of insomnia, especially in patients presenting with medical or psychiatric illnesses.

Inhibitor of Apoptosis (IAP) Antagonist Drug Pipeline Market Insights Report 2022 Featuring Merck & Co., Novartis, Astex Pharmaceuticals, Ascentage Pharma, & Chia Tai Tianqing Pharmaceutical - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
Health, General Health, IAP, Antagonist, Clinical trial, Neoplasm, Cell death, III, Route, News, T-cell lymphoma, Route of administration, IAPS, Merck & Co., Discovery, II, NDA, XIAP, Acquisition, Inhibitor of apoptosis, Administration, Therapy, Astex, CRT, Head, Patient, Pharmaceutical industry, Vaccine, Merck, Apoptosis

This "Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Inhibitor Of Apoptosis (IAP) Antagonist pipeline landscape.

Key Points: 
  • This "Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Inhibitor Of Apoptosis (IAP) Antagonist pipeline landscape.
  • The assessment part of the report embraces, in depth Inhibitor of Apoptosis (IAP) Antagonist commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their Inhibitor of Apoptosis (IAP) Antagonist drug candidates in the most advanced stage, i.e.
  • phase III include, Merck & Co.
    Inhibitor of Apoptosis (IAP) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

New Study Demonstrates Benefit of Advanced Decision Support in Driving Pharmacist Recommendations to Reduce Medication Risk

Retrieved on: 
Tuesday, August 16, 2022
Death, Journal of the American Geriatrics Society, Multimedia, Radius Ventures, Risk, CEO, Dementia, Science, Antagonist, Falls, Pharmacy, Research, American Geriatrics Society, Patient, PACE, View, ALS Therapy Development Institute, Delirium, Doctor of Philosophy, NASDAQ, Bachelor of Pharmacy, Journal, Solution, Urinary incontinence, Program, Organization, Pharmacist, Medicine, Pharmaceutical industry

MOORESTOWN, N.J., Aug. 16, 2022 /PRNewswire/ -- A new peer-reviewed study from Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, shows that pharmacist recommendations driven by its unique medication decision support system, MedWise® Science, can help prescribers identify and reduce the levels of potentially inappropriate medications among older adults, reducing the risk of negative cognitive and physical outcomes.

Key Points: 
  • The study, published in the Journal of the American Geriatrics Society, explored the dosage levels of urinary antimuscarinic medications with high anticholinergic properties.
  • MedWise Science uses the active ingredients from a participant's complete medication list, including over-the-counter drugs, to identify the risk of simultaneous, accumulative, multi-drug interactions, and predict the possibility of medication problems.
  • The research involved participants from 35 PACE organizations that use TRHC's comprehensive CareKinesis PACE Pharmacy and medication risk mitigation services.
  • TRHC offers comprehensive clinical pharmacy services for PACE organizations that provide ongoing medication assessments, comprehensive safety reviews, medication risk mitigation interventions, pharmacogenomic application, 24/7 medication management support, and adherence packaging, among other benefits.

Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 29, 2022
Pharmaceutical, Health, Clinical Trials, Therapy, Progesterone receptor, Antagonist, Pharmaceutical industry, Fine chemical

The "Progesterone Receptor (PR) Antagonist - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Progesterone Receptor (PR) Antagonist - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Progesterone Receptor (PR) Antagonist - Pipeline Insight, 2022" offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Progesterone Receptor (PR) Antagonist development.
  • The report assesses the active Progesterone Receptor (PR) Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.
  • Offers detailed therapeutic product profiles of Progesterone Receptor (PR) Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Market Insights 2022: Coverage of 15 Companies and Respective Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 29, 2022
Biotechnology, Health, Clinical Trials, Antagonist, Patient, Fibroblast growth factor receptor 4, HCC, Pemigatinib, II, FGFR4, Receptor tyrosine kinase, Therapy, FGFR2, Clinical trial, Discovery, Hepatocellular carcinoma, BTC, FGFR, News, Fine chemical, Pharmaceutical industry

This Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2022 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape.

Key Points: 
  • This Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2022 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist.
  • Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Therapeutic Assessment
    This segment of the report provides insights about the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drug candidates in the most advanced stage, i.e Phase III include, Helsinn.

Global Benign Prostatic Hyperplasia Therapeutics Market to 2030 - Increasing Awareness Toward Urological Disorders is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, June 27, 2022
Health, General Health, Ageing, Nocturia, Urinary tract infection, Patient, Man, Population, Exercise, Urine, Growth, Erectile dysfunction, Kidney, Disease, BPH, Type 2 diabetes, Administration for Community Living, Benign prostatic hyperplasia, Urinary retention, Urination, Awareness, Obesity, Woman, Office of Inspector General, U.S. Department of Health and Human Services, Therapy, Stone, U.S. Department of Defense Strategy for Operating in Cyberspace, CAGR, Environment, Semen, Antagonist, Urethra, Male, Prostate, American Urological Association, Quality of life, Human services, Risk, Prostate cancer, Time, Lower urinary tract symptoms, LUTS, Medical imaging, Pharmaceutical industry

The "Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class and Therapy Type: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class and Therapy Type: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global benign prostatic hyperplasia therapeutics market was valued at $5,697.70 million in 2020, and is estimated to reach $9,391.50 million by 2030, growing at a CAGR of 5.00% from 2021 to 2030.
  • Benign prostatic hyperplasia (BPH) is a non-malignant increase in the size of the prostate gland.
  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global benign prostatic hyperplasia therapeutics market to identify the prevailing opportunities.

Global Overactive Bladder Drug Forecast and Market Analysis Report 2021-2030 - Urovant Sciences Has Potential to Launch the First Gene Therapy in Overactive Bladder - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Diagnosis, Patient, Overactive bladder, R, Patent, Antagonist, Prevalence, Ageing, Urinary bladder, Knowledge, Social stigma, Industry, Toxin (comics), OAB, Review, Pharmaceutical industry

The "Overactive Bladder - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Overactive Bladder - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.
  • However, the launch of several pipeline products will provide a boost to market sales in the mid-to-late forecast period (2025-2030).
  • Analysis of the current and future market competition in the global OAB market.
  • 1.1 Overactive Bladder Market to Experience Moderate Growth, Reaching $2.8 Billion by 2030
    1.5 What Do Physicians Think?